Non-Surgical Rhinoplasty

What filler can change, and what it cannot

An updated systematic review in Aesthetic Plastic Surgery covered 30 studies and 9,657 patients, with hyaluronic acid used in 96.76 percent of treatments. Filler is commonly used for:

• Camouflaging a small dorsal hump, by adding volume above and below it so the profile reads as straighter.
• Lifting an under-projected or slightly drooping tip.
• Filling a depression or a saddle type contour where the bridge sits low.
• Smoothing minor irregularities, including some remaining after previous nasal surgery.

A separate systematic review of 16 studies and 652 patients reported satisfactory results in 93 percent of cases. That ranged from 75 to 100 percent across the individual studies, which treated problems suiting the method, so it is no prediction for any individual nose.

The published evidence is specific about the limits. Filler cannot address severe dorsal humps, significant deviation, significant changes in tip rotation, major structural problems, or breathing difficulty and nasal obstruction.

It cannot make a nose smaller: camouflaging a hump makes the nose marginally larger. It does nothing for a deviated septum, a narrow internal nasal valve or turbinate obstruction, which belong to functional surgery.

Reshaping the tip cartilage itself is tip plasty. Collapse and structural loss after previous surgery are revision territory.

What can go wrong, from redness to blindness

Most of what goes wrong is minor and usually settles. That review of 9,657 patients put overall complication incidence at 39.11 percent, mostly erythema and swelling at 27.95 percent.

The serious risk is different in kind. Filler injected into an artery, or compressing one, can block the blood supply to the skin and cause tissue death.

Travelling backwards into the ophthalmic circulation, it can block the blood supply to the eye and cause sudden, permanent blindness. It can also cause stroke.

In the same pooled review, serious vascular complications including blindness, skin necrosis and stroke were reported at up to 0.27 percent. Uncommon, and not reversible.

Hyaluronidase dissolves hyaluronic acid and helps an unwanted result or early skin level vascular compromise, but is far less reliable once the eye is involved. Reversibility is not safety.

What the published blindness cases show

A 2024 review in the Aesthetic Surgery Journal collated 511 published cases of filler induced blindness.

• The cases run from 1906 to 2023. Of them, 365 were published between September 2018 and March 2023.
• The nose was the most common site of all, at 40.6 percent of the recent cases and 37.4 percent across the whole period, ahead of the forehead and the glabella.
• Hyaluronic acid accounted for 79.6 percent of the recent cases, so a hyaluronic acid product does not remove this risk.
• Visual outcomes were documented in 318 cases. Of those, 6.0 percent recovered completely, 25.8 percent improved partially and 68.2 percent had no recovery at all.
• Central nervous system complications were present in 34.0 percent of cases, and 19.2 percent showed stroke like features.

Retrobulbar hyaluronidase improved vision in only 2 of 38 attempts, which is 5.3 percent. The authors state that prevention remains the most effective strategy, because no single treatment reached statistical significance.

How it is done, and how long it lasts

1. The sessionFiller is placed as controlled micro-boluses of no more than 0.1 mL per point, and as little as 0.02 mL near the tip.
2. The first daysBruising and swelling at the injection points are common. Many people return to normal activity the same day.
3. Months 8 to 12The result fades. Published data puts duration between about eight months and a year, and the 5,000 case series recorded 9 to 12 months.

That series of 5,000 treatments ran from 2015 to 2019 and was reported through the American Society of Plastic Surgeons. It averaged 0.72 mL, and signs of vascular occlusion occurred in 0.5 percent of cases, managed by restoring blood flow or by immediate hyaluronidase.

Those figures come from one experienced high volume practice and cannot be assumed to apply elsewhere.

Around 32 percent of that series returned for retreatment at 12 months, and each repeat carries the same risk profile as the first. Filler is not a rehearsal for surgery either: it adds where surgery would remove, so it cannot preview a reduction.

Filler or surgery

Surgery is not automatically better. It is not reversible, is usually carried out under general anaesthetic, and recovery runs to weeks with about a year of settling.

Neither is better in general: the choice turns on what you want changed. Size, structure and breathing are surgical questions.